Richard Aplenc Laboratory
Led by Richard Aplenc, MD, PhD, researchers in the Aplenc Laboratory are focused on improving the clinical outcomes of children with acute myeloid leukemia (AML). The long-term goal of the research conducted in the Aplenc Laboratory is to improve outcomes for children with AML by improving the delivery of currently available therapies and developing more effective and less toxic therapies.
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Oct;62(10):1775-81.
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R.
A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Med. 2015 Sep;4(9):1356-64.
Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R.
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Jul;62(7):1184-9.
Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R.